Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases.
AGTC's lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma; and 4D Molecular Therapeutics.
The company was founded in 1999 and is headquartered in Alachua, Florida.
- December 9, 2015 - 7:17am | Research Notes
- November 23, 2015 - 7:15am | Research Notes, News
- November 18, 2015 - 9:41am | Research Notes, Regulatory
- November 2, 2015 - 7:33am | Research Notes
- October 22, 2015 - 8:37am | Research Notes
- October 6, 2015 - 10:14am | Research Notes
- August 27, 2015 - 7:55am | Research Notes
- August 19, 2015 - 4:32pm | Research Notes
- July 26, 2015 - 11:46am | Research Notes
- July 18, 2015 - 3:33pm | Research Notes
- July 12, 2015 - 5:53pm | Research Notes
- July 5, 2015 - 3:07pm | Research Notes
- July 2, 2015 - 7:30am | Research Notes, News
- July 1, 2015 - 9:42am | Research Notes